Combining Calcitonin and Procalcitonin and Rheumatoid Arthritis-Related Biomarkers Improve Diagnostic Outcomes in Early Rheumatoid Arthritis

Figure 1

(a) Distribution of the serum PCT level in early RA, established RA, SLE, OA, GA, and healthy control groups. (b) Distribution of the level of serum PCT in early RA, established RA, SLE, OA, GA, and healthy control groups. (c) Distribution of the serum RF level in early RA, established RA, SLE, OA, GA, and healthy control groups. (d) Distribution of the serum anti-CCP level in early RA, established RA, SLE, OA, GA, and healthy control groups. (e) Distribution of the serum anti-RA33 level in early RA, established RA, SLE, OA, GA, and healthy control groups. RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; OA: osteoarthritis; GA: gouty arthritis; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; CT: calcitonin; PCT: procalcitonin; anti-CCP: anti-cyclic citrullinated peptide; anti-RA33: anti-RA33 antibodies.

(a)

(b)

(c)

(d)

(e)